Venous Leg Ulcer: Incidence and Prevalence in the Elderly

Overview

Journal J Am Acad Dermatol

Specialty Dermatology

Date 2002 Feb 28

PMID 11862173

Citations 107

Authors

David J Margolis

Warren Bilker

Jill Santanna

Mona Baumgarten

Affiliations

Soon will be listed here.

Abstract

Background: Venous leg ulcer is a disease most common in those aged 65 years and older. However, the incidence and prevalence have not been well established.

Objective: Our purpose was to estimate the prevalence and incidence of venous leg ulcers in the elderly.

Methods: We studied the General Practice Research Database, validated our case ascertainment strategy, and estimated the annual prevalence and incidence of venous leg ulcer.

Results: The positive predictive value of our ascertainment strategy was 98.3% (95% confidence interval [CI], 90.0, 100.0). The annual prevalence of venous leg ulcer among the elderly was 1.69 (95% CI, 1.65, 1.74). The overall incidence rate was 0.76 (95% CI, 0.71, 0.83) for men and 1.42 (1.35, 1.48) per 100 person-years for women.

Conclusion: Venous leg ulcer is a significant problem in those aged 65 years and older. As compared with previous studies, because we used medical records from a population of known size, our results are precise and less biased.

Citing Articles

New insights into the role of cellular senescence and chronic wounds.

Yang H, Zhang X, Xue B Front Endocrinol (Lausanne). 2024; 15:1400462.

PMID: 39558972 PMC: 11570929. DOI: 10.3389/fendo.2024.1400462.

L-PRF in extra-oral wound care.

Pinto N, Yu J, Koirala S, Mourao C, Andrade C, Rescigno E Periodontol 2000. 2024; 97(1):342-362.

PMID: 39305000 PMC: 11808448. DOI: 10.1111/prd.12605.

Chronic Venous Disease of the Lower Extremities: A State-of-the Art Review.

Attaran R, Carr J J Soc Cardiovasc Angiogr Interv. 2024; 2(1):100538.

PMID: 39132527 PMC: 11307564. DOI: 10.1016/j.jscai.2022.100538.

Evaluation of a Semi-Automated Wound-Halving Algorithm for Split-Wound Design Studies: A Step towards Enhanced Wound-Healing Assessment.

Georg P, Schmid M, Zahia S, Probst S, Cazzaniga S, Hunger R J Clin Med. 2024; 13(12).

PMID: 38930128 PMC: 11205086. DOI: 10.3390/jcm13123599.

Cost-effectiveness analysis of intralesional and perilesional recombinant human epidermal growth factor vs hydrocolloid therapy in venous ulcer treatment in the Colombian context.

Cacua Sanchez M, Botero A, Moreno-Mattar O J Vasc Surg Venous Lymphat Disord. 2023; 12(2):101745.

PMID: 38145819 PMC: 11523390. DOI: 10.1016/j.jvsv.2023.101745.